REPROCELL Receives Commercialization Award from Maryland Stem Cell Research Fund to Advance Universal, Hypoimmune iPSC Platforms
The award will fund REPROCELL’s development of clinical-grade lines and a modular gene insertion platform designed to improve scalability, regulatory readiness, and access to off-the-shelf cell therapies.
Key Points
- REPROCELL has received a Commercialization Award from the Maryland Stem Cell Research Fund to support development of clinical-grade hypoimmune induced pluripotent stem cell (iPSC) seed stocks.
- The project combines REPROCELL’s StemRNA reprogramming platform with StemEdit, an AI-designed CRISPR-based gene editing technology, to build universal iPSC platforms for clinical use.
- The program also includes development of a modular landing pad platform and preparation of a Drug Master File to support future manufacturing and regulatory use.
Demand for iPSC thearpies has significantly grown, however, at least for scalable, allogeneic off-the-shelf approaches, the manufacturing and immune-compatibility continue to limit the broader use. To help tackle that, REPROCELL has received a Commercialization Award from the Maryland Stem Cell Research Fund to advance universal, clinical-grade, hypoimmune-induced pluripotent stem cell (iPSC) platforms.
The award is part of the fund’s latest financing cycle focused on regenerative medicine technologies and stem cell-based therapies in Maryland. REPROCELL said the work will support broader access to universal cell technologies by manufacturing in its U.S. cleanrooms and by preparing a regulatory Drug Master File.
Reprogramming, gene editing, and manufacturing
The project aims to accelerate the manufacturing of clinical-grade hypoimmune iPSCs by combining REPROCELL’s StemRNA reprogramming platform with StemEdit, an AI-designed CRISPR-based gene-editing technology.
The company also plans to advance a modular landing pad platform that allows insertion of therapeutic genes into genomic safe harbor loci within iPSCs. According to REPROCELL, this plug-and-play approach is intended to simplify development workflows for future cell and gene therapies and improve manufacturing scalability and consistency.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
